- Alcon reported Q2 2024 revenue of $2.496 billion, up 3.06% year over year and 1.50% quarter over quarter, with a gross margin of 55.05%. Operating income was $318 million, delivering an operating margin of 12.74%, and net income totaled $223 million (EPS of $0.45). These results reflect a durable mix of Surgical and Vision Care products and steady demand in ophthalmology markets.
- The company generated strong cash flow, with net cash provided by operating activities of $530 million and free cash flow of $410 million (after $120 million of capex). Cash and equivalents stood at $1.372 billion at quarter end, while gross debt totaled $5.089 billion and net debt was $3.717 billion, yielding a solid liquidity position and capital-allocation flexibility. Equity remains robust at $20.931 billion, supported by substantial intangible assets and goodwill.
- Profitability metrics improved versus prior-year levels but remain sensitive to the asset-intensive business model. Net income rose 31.95% year over year, while YoY EPS grew 32.35%, yet the company’s ROE is modest at approximately 1.06% and ROA around 0.75%, reflecting a large asset base and ongoing investments in R&D and product platforms. QoQ, revenue and earnings experienced modest deceleration in some lines, consistent with seasonality and product mix shifts.
- The outlook is favorable for steady cash generation and continued market share gains in high-growth ophthalmic segments, though the absence of formal forward guidance in the data requires observers to monitor currency impacts, competitive dynamics, and new product cycles. Overall, the QQ2 performance reinforces Alcon’s position as a high-quality cash-generative ophthalmology franchise with attractive free cash flow to support deleveraging and shareholder-friendly capital allocation.